



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 22, 2009

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0776, Phase II Trial of Avastin® in Combination with Sorafenib in Recurrent Glioblastoma Multiforme

The following forms have been updated:

- Evaluation/Treatment Form: Deleted all reference to treatment of Sorafenib, Days 1 through 14 which include:
 - Sorafenib schedule followed: question removed in its entirety
 - Footnote: *Sorafenib: "... or days 1 through 14"
- Pathology Submission Form now reads "Dr. Caterina Giannini **and/or associates**, Mayo Clinic Rochester – Rochester, MN"
- Blood Specimen Submission Form now reads "Time Point: 2-Cycle 1, Day 3 (**± 1 day**)"

Also, please note that a Reimbursement Request Form has been added.

If you have any questions, please feel free to contact me.

Enclosure